Please wait while the formulary information is being retrieved.
ILEVRO (NEPAFENAC)
- Post-op ocular inflammation
- Postoperative ocular pain
0.3 % eye drops,suspension
- Instill 1 drop to the operated eye by ophthalmic route once daily ; start 1 day before cataract surgery; use for 14 days after surgery
Post-op ocular inflammation
- Instill 1 drop to the operated eye by ophthalmic route once daily beginning 1 day prior to surgery, continued on day of surgery and throughthe first 2 weeks of post-operative period. Instill 1 additional drop30-120 minutes before surgery.
- Instill 1 drop to the operated eye by ophthalmic route once daily ; start 1 day before cataract surgery; use for 14 days after surgery
Postoperative ocular pain
- Instill 1 drop to the operated eye by ophthalmic route once daily beginning 1 day prior to surgery, continued on day of surgery and throughthe first 2 weeks of post-operative period. Instill 1 additional drop30-120 minutes before surgery.
- Instill 1 drop to the operated eye by ophthalmic route once daily ; start 1 day before cataract surgery; use for 14 days after surgery
- None
Contraindicated
- None
Severe
Moderate
- None
- Corneal epithelial degeneration
- Corneal erosion
- Corneal ulcer
- Perforation of cornea
Contraindicated
- Keratitis
- Ocular hemorrhage
Severe
Moderate
- Decreased corneal sensitivity
- Diabetes mellitus
- Impaired wound healing
- Increased risk of bleeding
- Rheumatoid arthritis
- Tear film insufficiency
ILEVRO (NEPAFENAC)
- Post-op ocular inflammation
- Postoperative ocular pain
- Corneal opacity
- Ocular hypertension
- Reduced visual acuity
- Foreign body sensation of eye
- Sticky sensation of eye
More Frequent
Severe
Less Severe
- Chemosis
- Conjunctival hyperemia
- Corneal edema
- Ocular pain
- Sinusitis
- Vitreous detachment
- Dry eye
- Eye tearing
- Eyelash crusting
- Headache disorder
- Hypertension
- Nausea and vomiting
- Ocular irritation
- Ocular itching
- Photophobia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Corneal erosion
- Corneal ulcer
- Impaired wound healing
Less Severe
- Corneal dystrophy
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Nepafenac
Safety and efficacy not established age < 10 years.
- 1 Day – 10 Years
- Safety and efficacy not established age < 10 years.
Nepafenac
- Severity Level:
C
- Additional Notes: Syst absorp unknown; not rec 3rd trimest, premature closure duct arteriosus risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Nepafenac
Drug excreted in rat studies, insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Drug excreted in rat studies, insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Post-op ocular inflammation | |
| H57.8 | Other specified disorders of eye and adnexa |
| Postoperative ocular pain | |
| H57.1 | Ocular pain |
| H57.10 | Ocular pain, unspecified eye |
| H57.11 | Ocular pain, right eye |
| H57.12 | Ocular pain, left eye |
| H57.13 | Ocular pain, bilateral |
| 0-9 | A-Z |
|---|---|
| H57.1 | Ocular pain |
| H57.10 | Ocular pain, unspecified eye |
| H57.11 | Ocular pain, right eye |
| H57.12 | Ocular pain, left eye |
| H57.13 | Ocular pain, bilateral |
| H57.8 | Other specified disorders of eye and adnexa |
Formulary Reference Tool